31 research outputs found

    Part A: Hendrickson reagent๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ N-Boc carbamate๋กœ๋ถ€ํ„ฐ ํ˜•์„ฑ๋œ isocyanate์˜ cyclization ๋ฐ urea formation์— ๋Œ€ํ•œ ์‘์šฉ. Part B: ํ•ญ๋น„๋งŒ์— ํšจ๊ณผ์ ์ธ NED-240์˜ ๋ฐœ๊ตด ๋ฐ QSAR ๋ชจ๋ธ ์„ค๊ณ„์™€ ์‘์šฉ.

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์•ฝํ•™๋Œ€ํ•™ ์•ฝํ•™๊ณผ ์•ฝํ’ˆํ™”ํ•™์ „๊ณต, 2016. 2. ๊น€์ƒํฌ.Part A: Isocyanates๋Š” ๋‹ค์–‘ํ•œ electrophilic addition ํ˜น์€ cycloaddition reactions์— ์‘์šฉ๋˜์–ด ๋ณต์žกํ•œ ๊ตฌ์กฐ์˜ ํ™”ํ•ฉ๋ฌผ์„ ๋งŒ๋“ค ๋•Œ ์“ฐ์ผ ์ˆ˜ ์žˆ๋Š” ์ค‘์š”ํ•œ ์ค‘๊ฐ„์ฒด๋กœ ๋„๋ฆฌ ์‚ฌ์šฉ๋œ๋‹ค. Hofmann, Curtius, Lossen rearrangement๋“ฑ named reaction์—์„œ isocyanate๊ฐ€ ์ค‘๊ฐ„์ฒด๋กœ ํ˜•์„ฑ๋˜๋ฉฐ halosilane, phosphorus pentachlroride ์™€ chloroborane ๊ฐ™์€ ์‹œ์•ฝ๋“ค์„ ์‚ฌ์šฉํ•˜์—ฌ carbamate functional group์œผ๋กœ๋ถ€ํ„ฐ isocyante๋ฅผ ํ•ฉ์„ฑํ•˜๋Š” ๋ฐฉ๋ฒ•๋“ค์ด ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ์ด๋Ÿฌํ•œ ๋ฐ˜์‘๋“ค์€ ์ฃผ๋กœ N-methoxycarbonyl (Moc) ํ˜น์€ N-benzyloxycarbonyl (Cbz) ๋ฅผ ๊ฐ€์ง€๊ณ  ์žˆ๋Š” ๊ธฐ์งˆ๋“ค์„ ์‚ฌ์šฉํ•˜๋ฉฐ N-tert-butyloxycarbonyl (Boc) group ์— ๋Œ€ํ•œ ๋ฐ˜์‘์„ฑ์€ ๋ฏธ๋ฏธํ•˜๋‹ค๊ณ  ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ํ˜„์žฌ๊นŒ์ง€ ์•Œ๋ ค์ง„ isocyanate๋ฅผ ํ˜•์„ฑํ•˜๋Š” ๋ฐฉ๋ฒ•๋“ค ์ค‘ ๋‹ค๋ฅธ carbamate ๊ธฐ์งˆ๋“ค์— ๋น„ํ•ด N-Boc carbamate ๊ธฐ์งˆ์„ ์„ ํƒ์ ์œผ๋กœ ์‚ฌ์šฉํ•˜๋Š” ๋ฐฉ๋ฒ•์€ ์ž˜ ์•Œ๋ ค์ ธ ์žˆ์ง€ ์•Š๋‹ค. ์ด์— ๋ณธ ๋…ผ๋ฌธ์—์„œ๋Š” Hendrickson POP reagent๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ N-Boc carbamate๋ฅผ ๋ณด๋‹ค ์„ ํƒ์ ์œผ๋กœ isocyanate๋กœ ์ „ํ™˜ํ•˜๋Š” ๋ฐฉ๋ฒ•์— ๋Œ€ํ•˜์—ฌ ์„ค๋ช…ํ•˜๊ณ ์ž ํ•œ๋‹ค. ์ด๋ ‡๊ฒŒ ํ˜•์„ฑ๋œ isocyanate๋Š” ๋” ๋‚˜์•„๊ฐ€ Friedel-Crafts-type cyclization ๋ฐ urea formation์— ์‘์šฉ๋˜์–ด ๋”์šฑ ํšจ์œจ์ ์œผ๋กœ ์‚ฌ์šฉ ๋  ์ˆ˜ ์žˆ๋‹ค. ์ตœ์ ํ™” ๋œ ๋ฐ˜์‘ ์กฐ๊ฑด์— ์˜ํ•ด heterocyclic lactam๊ณผ urea๋ฅผ ๋†’์€ ์ˆ˜๋“๋ฅ ๋กœ ์–ป์„ ์ˆ˜ ์žˆ์œผ๋ฉฐ ์ด๋Ÿฌํ•œ ๋ฐฉ๋ฒ•์€ ๋ณต์žกํ•œ ๊ตฌ์กฐ์˜ alkaloid๋‚˜ ์ฒœ์—ฐ๋ฌผ์˜ ํ•ฉ์„ฑ์— ์‘์šฉ๋  ์ˆ˜ ์žˆ์œผ๋ฆฌ๋ผ ๊ธฐ๋Œ€ํ•œ๋‹ค. Part B: ๋น„๋งŒ ์–ต์ œ์ œ๋Š” ํ˜„๋Œ€์‚ฌํšŒ์—์„œ ๊ฐ๊ด‘๋ฐ›๋Š” ์•ฝ๋ฌผ์ด์ง€๋งŒ ์•ฝ๋ฌผ์˜ ํŠน์„ฑ์ƒ ์žฆ์€ ์‹ฌ์žฅ๋ณ‘ ๋ฐ ์‹ฌํ˜ˆ๊ด€๊ณ„ ๋ถ€์ž‘์šฉ์œผ๋กœ ์ธํ•˜์—ฌ ์‚ฌ์šฉ์ด ์ œํ•œ๋˜๊ณ  ์žˆ๋‹ค. ์ด์— ๋ณด๋‹ค ์•ˆ์ „ํ•˜๊ณ  ํšจ๊ณผ์ ์ธ ํ•ญ๋น„๋งŒ ์•ฝ๋ฌผ์„ ๊ฐœ๋ฐœํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ์•ฝ 250๊ฐœ ์ •๋„์˜ piper-amide ๊ณ„์—ด์˜ ์œ ๋„์ฒด library screening์„ ํ†ตํ•ด ๊ฐ€์žฅ ํšจ๊ณผ๊ฐ€ ์ข‹์€ NED-240์„ ๋ฐœ๊ตด ํ•˜์˜€๋‹ค. ์ด ๋ฌผ์งˆ์€ ๋™๋ฌผ ์‹คํ—˜์„ ํ†ตํ•˜์—ฌ ํ•ญ๋น„๋งŒ ํšจ๊ณผ๋ฅผ ์ž…์ฆํ•˜์˜€์œผ๋ฉฐ ๋…์„ฑ๋„ ๊ฑฐ์˜ ์—†์–ด ์ฐจ์„ธ๋Œ€ ํ•ญ๋น„๋งŒ ์•ฝ๋ฌผ๋กœ์„œ์˜ ์„ ๋„๋ฌผ์งˆ๋กœ์„œ์˜ ๊ฐ€๋Šฅ์„ฑ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค. ์ถ”๊ฐ€์ ์œผ๋กœ screening ๊ฒฐ๊ณผ๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ QSAR๋ชจ๋ธ์„ ๊ตฌ์ถ•ํ•จ์œผ๋กœ์จ ํ™œ์„ฑ๊ณผ ์ƒ๊ด€๊ด€๊ณ„๊ฐ€ ์žˆ๋Š” ๊ตฌ์กฐ์ ์ธ ํŠน์„ฑ์„ ํŒŒ์•…ํ•˜์˜€์œผ๋ฉฐ, ์ด๋ฅผ ๋‹ค์–‘ํ•œ scaffold์™€ ํƒ€์ผ“์„ ๊ฐ€์ง€๊ณ  ์žˆ๋Š” 1700๊ฐœ ์ •๋„์˜ small molecules library๋ฅผ ํ†ตํ•˜์—ฌ validation์„ ํ•˜์˜€๋‹ค. ๊ทธ ๊ฒฐ๊ณผ ๋น„๋งŒ ์น˜๋ฃŒ์— ํšจ๊ณผ์ ์ผ ๊ฒƒ ์ด๋ผ๊ณ  ์˜ˆ์ธก๋˜๋Š” ํ™”ํ•ฉ๋ฌผ 40๊ฐœ๋ฅผ ๋„์ถœํ•ด๋‚ด์—ˆ๊ณ  ๊ทธ ์ค‘ ๊ตฌ์กฐ์  ์œ ์‚ฌ์„ฑ ๋ฐ ์‹œ์ค‘ ๊ตฌ์ž… ๊ฐ€๋Šฅ ์—ฌ๋ถ€๋ฅผ ๊ณ ๋ คํ•ด ์„ ์ •๋œ ์„ธ๊ฐ€์ง€ ๋ฌผ์งˆ์„ Oil Red O staining์„ ํ†ตํ•ด ํ•ญ๋น„๋งŒ ํšจ๊ณผ๊ฐ€ ์žˆ๋Š”์ง€ ์•Œ์•„๋ณด์•˜๋‹ค. ๊ทธ ๊ฒฐ๊ณผ๋กœ NED-240๊ณผ ์œ ์‚ฌํ•œ ์ •๋„์˜ ํ™œ์„ฑ์„ ๋„๋Š” TWS119๋ฅผ ๋„์ถœํ•  ์ˆ˜ ์žˆ์—ˆ๊ณ , ์•„์ง NED-240์˜ ์ž‘์šฉ ๊ธฐ์ „์ด ๋ช…๋ฐฑํ•˜์ง€ ์•Š์•„ TWS119์˜ ํƒ€๊ฒŸ์ธ GSK-3ฮฒ ์— ๋Œ€ํ•ด ์ถ”๊ฐ€์ ์ธ ํ™œ์„ฑ ์—ฌ๋ถ€ ์‹คํ—˜์„ ์‹ค์‹œํ•  ๊ณ„ํš์ด๋‹ค.Part A. Hendrickson reagentmediated transformation of NBoc carbamates to isocyanate and its applications 1 Introduction 2 Results and discussion 3 Conclusion 9 Experimental Section 10 References 18 Spectral Data 19 Part B: Discovery of a novel anti-obesity agent and in silico approach for target identification 24 Introduction 25 Results and discussion 26 Conclusion 29 Experimental Section 30 References 31 Abstract in Korean 32Maste

    ์›๋ฐœ์„ฑ์ค‘์ถ”์‹ ๊ฒฝ๊ณ„๋ฆผํ”„์ข…์˜ ์œ ์ „ํ•™์  ํŠน์„ฑ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› ์˜๊ณผ๋Œ€ํ•™ ์˜ํ•™๊ณผ, 2017. 8. ํ—ˆ๋Œ€์„.๋ชฉ์  : MYD88๊ณผ CD79B ๋Œ์—ฐ๋ณ€์ด๋Š” nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB) ์‹ ํ˜ธ์ฒด๊ณ„์˜ ๊ตฌ์กฐ์  ํ™œ์„ฑํ™” (constitutive activation)์— ๊ด€์—ฌํ•˜๋ฉฐ ๋ฆผํ”„์ข…์˜ ์ƒˆ๋กœ์šด ์น˜๋ฃŒ ํ‘œ์ ์œผ๋กœ ์—ฐ๊ตฌ๋˜๊ณ  ์žˆ๋‹ค. ์›๋ฐœ์„ฑ์ค‘์ถ”์‹ ๊ฒฝ๊ณ„๋ฆผํ”„์ข… (Primary Central Nervous System Lymphoma, PCNSL)์˜ MYD88 ๋ฐ CD79B ๋Œ์—ฐ๋ณ€์ด์˜ ๋นˆ๋„๋ฅผ ํ™•์ธํ•˜๊ณ , ์ „์ฒด ์œ ์ „์ฒด ์—ผ๊ธฐ์„œ์—ด๋ถ„์„ (Whole genome sequencing, WGS)์„ ํ†ตํ•ด PCNSL์˜ ์œ ์ „ํ•™์  ํŠน์„ฑ์„ ๊ทœ๋ช…ํ•˜๊ณ ์ž ํ•œ๋‹ค. ๋ฐฉ๋ฒ• : ์กฐ์งํ•™์ ์œผ๋กœ PCNSL๋กœ ์ง„๋‹จ๋œ ํ™˜์ž๋“ค ์ค‘ ํฌ๋ฅด๋ง๋ฆฐ๊ณ ์ • ํŒŒ๋ผํ•€ํฌ๋งค ์กฐ์ง ๊ฒ€์ฒด๊ฐ€ ์žˆ๋Š” 115๋ช… ํ™˜์ž๊ตฐ (cohort A)์—์„œ MYD88 TIR (Toll/IL-1 receptor) ๋„๋ฉ”์ธ ์ค‘ exon 5์™€ CD79B ITAM (immunoreceptor tyrosine-based activation motif)์˜ exon 5์˜ ๋Œ์—ฐ๋ณ€์ด ํ™•์ธ์„ ์œ„ํ•ด ์ƒ์–ด ์—ผ๊ธฐ์„œ์—ด ๋ถ„์„ (Sanger sequencing)์„ ํ–ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ์‹ ์„ ๋™๊ฒฐ์กฐ์ง์ด ์žˆ๋Š” 10๋ช… (cohort B)์—์„œ ์ข…์–‘(๋‡Œ)๊ณผ ๋ง์ดˆํ˜ˆ์•ก(๋Œ€์กฐ๊ตฐ)์˜ WGS์„ ํ–ˆ๊ณ  sequencing ํ‰๊ท  depth๋Š” ์ข…์–‘์€ 64.2x, ๋ง์ดˆํ˜ˆ์•ก์€ 33.6x์˜€๋‹ค. ๊ฒฐ๊ณผ : Cohort A 115๋ช… ์ค‘ MYD88 exon 5์˜ ์ค‘ํ•ฉํšจ์†Œ ์—ฐ์‡„ ๋ฐ˜์‘ ( Polymerase Chain Reaction, PCR) ์ˆ˜ํ–‰ ๋ฐ ํŒ๋…์ด ๊ฐ€๋Šฅํ–ˆ๋˜ 94๋ช…์ค‘ 33๋ช… (35.1%)์—์„œ MYD88 L265P (CTG>CCG) ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ์žˆ์—ˆ๋‹ค. CD79B exon 5์˜ PCR ์ˆ˜ํ–‰ ๋ฐ ํŒ๋…์ด ๊ฐ€๋Šฅํ–ˆ๋˜ 113๋ช…์ค‘ 25๋ช… (22.1%)์—์„œ CD79B ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ์žˆ์—ˆ๊ณ , 25๊ฐœ์˜ ๋Œ์—ฐ๋ณ€์ด๋Š” Y196C (TAC>TGC, 8๋ช…), Y196H (TAC>CAC, 7๋ช…), Y196S (TAC>TCC, 5๋ช…), Y196N (TAC>AAC, 4๋ช…) ์™€ Y196F (TAC>TTC, 1๋ช…) ์˜€๋‹ค. MYD88 L265P ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ์žˆ๋Š” 33๋ช… ์ค‘ 13๋ช…์—์„œ CD79B ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ํ•จ๊ป˜ ์žˆ์—ˆ๋‹ค. ์ฆ‰ MYD88 L265P ๋Œ์—ฐ๋ณ€์ด ํ™˜์ž์˜ 39.3%, CD79B ๋Œ์—ฐ๋ณ€์ด ํ™˜์ž์˜ 52.0%๊ฐ€ ๋‘ ๊ฐ€์ง€ ๋Œ์—ฐ๋ณ€์ด๋ฅผ ํ•จ๊ป˜ ๊ฐ€์ง€๊ณ  ์žˆ์—ˆ๋‹ค. Cohort B 10๋ช…์˜ WGS์—์„œ ์ฒด์„ธํฌ ๋Œ์—ฐ๋ณ€์ด์— ๋Œ€ํ•œ Mutec2/MutSig ๋ถ„์„์—์„œ ํ†ต๊ณ„ํ•™์ ์œผ๋กœ ์œ ์˜ํ•˜๊ฒŒ (q CTA), R231Q (CGG>CAG)์˜€๋‹ค. MYD88 P258L์€ ๋งŒ์„ฑ๋ฆผํ”„๊ตฌ์„ฑ๋ฐฑํ˜ˆ๋ณ‘, ์›๋ฐœ์„ฑ์œ ๋ฆฌ์ฒด๋ง๋ง‰๋ฆผํ”„์ข…์—์„œ์˜ ๋ณด๊ณ ์— ์ด์–ด 3๋ฒˆ์งธ์ด๋ฉฐ, R231Q๋Š” ๋ณด๊ณ ๋œ ์ ์ด ์—†๋Š” ์ƒˆ๋กœ์šด ๋Œ์—ฐ๋ณ€์ด์˜€๋‹ค. P258L์™€ R231Q์€ Sanger sequencing์œผ๋กœ ๊ฒ€์ฆ (validation) ํ–ˆ๋‹ค. CD79B ๋Œ์—ฐ๋ณ€์ด๋Š” 7๋ช… (70%)์—์„œ ์žˆ์—ˆ๊ณ  5๋ช…์—์„œ MYD88/CD79B ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ํ•จ๊ป˜ ์žˆ์—ˆ๋‹ค. ์ตœ๊ทผ์— ๋ฐœํ‘œ๋œ 4๊ฐœ์˜ PCNSL ์ „์ฒด ์—‘์†œ ์—ผ๊ธฐ์„œ์—ด๋ถ„์„๋ฒ• (whole exome sequencing, WES) ์—ฐ๊ตฌ๊ฒฐ๊ณผ์—์„œ ๊ฐ ์—ฐ๊ตฌ์—์„œ 30%์ด์ƒ์˜ ๋นˆ๋„๋กœ ์กด์žฌํ•œ ๋Œ์—ฐ๋ณ€์ด ์œ ์ „์ž 46๊ฐœ๋ฅผ ์„ ๋ณ„ํ•˜์—ฌ cohort B์—์„œ ๋ถ„์„ํ•œ ๊ฒฐ๊ณผ 30%์ด์ƒ์˜ ๋นˆ๋„๋กœ ์ฃผ์š” 3๊ฐ€์ง€ ๋ณ€์ด (non-synonymous single-nucleotide polymorphism (Nonsyn SNP), frameshift insertion/deletion (frameshift INDEL), exonic structural variation (exonic SV))๊ฐ€ ์žˆ์—ˆ๋˜ ์œ ์ „์ž๋Š” ์ด 24๊ฐœ์˜€๊ณ , ๊ทธ ์ค‘ Nonsyn SNP๊ฐ€ 30%์ด์ƒ์—์„œ ์žˆ์—ˆ๋˜ ๊ฒƒ์€ MYD88, CD79B, PCLO, LRP1B, TENM4์˜€๋‹ค. ๋ณธ ์—ฐ๊ตฌ ํฌํ•จ 5๊ฐœ ์ค‘ 3๊ฐœ ์ด์ƒ์˜ ์—ฐ๊ตฌ์—์„œ PCNSL์—์„œ ๊ณตํ†ต์ ์œผ๋กœ ๋ฐ˜๋ณต๋˜๋Š” ๋Œ์—ฐ๋ณ€์ด ์œ ์ „์ž๋Š” MYD88, PIM1, IGLL5, TBL1XR1, BTG1, DUSP2, ETV6๋กœ ์ด 46๊ฐœ ์œ ์ „์ž์ค‘ 7๊ฐœ (17%)์˜€๋‹ค. ์ค‘์ถ”์‹ ๊ฒฝ๊ณ„ ํŽธํ–ฅ์„ฑ (CNS tropism)๊ณผ ๊ด€๋ จํ•œ ์œ ์ „์ž ๋ถ„์„์—์„œ TENM4์˜ nonsyn SNP๊ฐ€ 30%์—์„œ ์žˆ์—ˆ๊ณ , SPP1(20%), SLC16A9 (20%), MDM2 (30%), YEATS4 (30%)์—์„œ ๊ตฌ์กฐ์  ๊ฒฐ์† (structural deletion) ์ด ์กด์žฌํ–ˆ๋‹ค. 10๋ช… ์ค‘ 8๋ช…์—์„œ OZD4, SPP1, SLC16A9, MDM2, YEATS4์ค‘ 1๊ฐœ ์ด์ƒ์—์„œ ์ฃผ์š” ๋ณ€์ด๊ฐ€ ์กด์žฌํ–ˆ๋‹ค. ๊ฒฐ๋ก  : MYD88์™€ CD79B์˜ ๋Œ์—ฐ๋ณ€์ด๋Š” PCNSL์˜ ํŠน์ง•์ ์ธ ์œ ์ „์ž ๋ณ€์ด์ด๋‹ค. MYD88์—์„œ L265P๋ฟ ์•„๋‹ˆ๋ผ P258L, R231Q์˜ ์กด์žฌ๋ฅผ ํ™•์ธํ–ˆ๊ณ  R231Q๋Š” ์ฒซ ๋ฒˆ์งธ ๋ณด๊ณ ์ด๋‹ค. TENM4์˜ ๋Œ์—ฐ๋ณ€์ด๋Š” PCNSL์˜ ์ค‘์ถ”์‹ ๊ฒฝ๊ณ„ ํŽธํ–ฅ์„ฑ์„ ์„ค๋ช…ํ•  ์ˆ˜ ์žˆ๋Š” ๊ธฐ์ „ ์ค‘ ํ•˜๋‚˜์ด๋‹ค.1. ์„œ๋ก ..........................................................................1 2. ์—ฐ๊ตฌ๋Œ€์ƒ ๋ฐ ๋ฐฉ๋ฒ•.................................................5 3. ์—ฐ๊ตฌ๊ฒฐ๊ณผ................................................................11 4. ๊ณ ์ฐฐ........................................................................36 5. ์ฐธ๊ณ ๋ฌธํ—Œ...............................................................42 ์™ธ๊ตญ์–ด์ดˆ๋ก................................................................48Docto

    (The)Effect of green tea drinking on development of dental caries among elementary school children

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์น˜์˜ํ•™๊ณผ ์˜ˆ๋ฐฉ์น˜ํ•™์ „๊ณต,2006.Docto

    ์ง„ํ–‰์„ฑ ํ์•” ํ™˜์ž์—์„œ ํ•ญ์•” ํ™”ํ•™์š”๋ฒ• ํ›„ ํ๋ ด ๋ฐœ์ƒ์˜ ์œ„ํ—˜์ธ์ž๋“ค

    No full text
    Thesis(masters) --์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์˜ํ•™๊ณผ (๋ถ„์ž์ข…์–‘์˜ํ•™์ „๊ณต),2009.2.Maste

    ๅญธ็ˆถๆฏ์˜ ๅญธๆ ก็นผ็บŒๅฃ่…”ๅฅๅบท็ฎก็†ไบ‹ๆฅญ์— ้—œํ•œ ็Ÿฅ่ญ˜ๆฐดๆบ–๊ณผ ๆ”ฏๆŒ็จ‹ๅบฆ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์น˜์˜ํ•™๊ณผ ์˜ˆ๋ฐฉ์น˜ํ•™ ์ „๊ณต,2001.Maste
    corecore